Celldex Therapeutics price to sales ratio CLDX

Market value divided by revenue over the last twelve months, since 2012.

Today, Oct 23, 2026: n/m; a sliver of sales
Last meaningful: 195×; Aug 2025
10-year median: 34.9×
10-year range: 3.1× to 200×
Peer median: 6.7×

Celldex Therapeutics' price to sales ratio is not a meaningful number today: a multiple this high rests on a sliver of sales.

It was last meaningful in Aug 2025, at 195×.

On the days it had one over the last ten years, its median was 34.9×, from 3.1× in Dec 2018 to 200× in May 2021.

Price to sales ratio over time

median 34.9×

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2025	195×	149×	197×
2024	169×	157×	182×
2023	n/m a value too high to mean anything
2022	174×	160×	184×
2021	200×	111×	200×
2020	153×	5.6×	199×
2019	8.0×	3.7×	9.2×
2018	3.1×	3.1×	37.2×
2017	34.6×	31.6×	65.5×
2016	53.5×	53.5×	158×
2015	n/m a value too high to mean anything
2014	n/m a value too high to mean anything
2013	198×	43.9×	198×
2012	41.3×	25.5×	41.6×

Against its peers

Companies in Medical - Diagnostics & Research nearest Celldex Therapeutics' size, closest first, today.

Company	Price to sales ratio
CLDXCelldex Therapeutics	n/m
CDNACareDx	7.8×
VCYTVeracyte	6.9×
BLLNBillionToOne	12.8×
LNTHLantheus	4.2×
CAICaris Life Sciences	9.1×
BIOBio-Rad Laboratories	3.8×
NRCNRC Health	3.5×
RVTYRevvity	6.1×
MEDPMedpace	6.7×
Peer median	6.7×

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Celldex Therapeutics

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.